Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Last trade$0.081
Day change-$0.0012 (-1.46%)
Day range$0.0731 – $0.0915
Volume802,272
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.61M
Price / earnings
—
Price / book
-0.42×
Price / sales
0.08×
EV / sales
0.39×
EV / EBITDA
-0.39×
Profitability
Earnings per share
-$1.27
Return on assets
-105.44%
Return on equity
667.29%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-2.17×
Current ratio
0.21×
Quick ratio
0.21×
Cash ratio
0.09×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.01M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VVOS, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$5.15M
$5.14M
$3.82M
$6.78M
$3.82M
$3.02M
$3.7M
$3.86M
Cost of revenue
$2.2M
$2.08M
$836K
$2.85M
$1.71M
$1.51M
$1.6M
$1.53M
Gross profit
$2.95M
$3.06M
$2.99M
$3.94M
$2.11M
$1.51M
$2.1M
$2.33M
Selling, general and administrative
$7.27M
$9.22M
$8.93M
$8.29M
$6.67M
$5.25M
$4.76M
$4.83M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$7.78M
$9.67M
$9.37M
$8.67M
$6.98M
$5.43M
$4.9M
$4.98M
Operating income
-$4.83M
-$6.62M
-$6.38M
-$4.73M
-$4.87M
-$3.92M
-$2.81M
-$2.65M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$5.52M
-$7.75M
-$6.95M
-$5.4M
-$5.01M
-$3.86M
-$2.83M
-$2.62M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$5.52M
-$7.75M
-$6.95M
-$5.4M
-$5.01M
-$3.86M
-$2.83M
-$2.62M
Net income attributable to common shareholders
-$5.48M
-$7.68M
-$6.89M
-$5.4M
-$5.01M
-$3.86M
-$2.83M
-$2.62M
EBITDA
-$4.31M
-$6.16M
-$5.94M
-$4.35M
-$4.56M
-$3.74M
-$2.66M
-$2.5M
Basic earnings per share
-$0.31
-$0.52
-$0.55
-$0.49
-$0.55
-$0.45
-$0.36
-$0.40
Diluted earnings per share
-$0.31
-$0.52
-$0.55
-$0.49
-$0.55
-$0.45
-$0.36
-$0.40
Recent news
Company coverage with links to the original publishers.
Vivos Therapeutics reported a Q3 loss of $0.07 per share, beating consensus estimates of $0.30 loss by 76.67%. Revenue came in at $6.41 million, surpassing estimates by 17.15%, though down from $6.78 million year-ago. The stock has declined 95.2% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Vivos Therapeutics reported Q3 2026 revenue of $6.4 million, up 24% quarter-over-quarter, with operating loss improving 18% year-over-year to $3.9 million. The company reduced annual operating costs by $5 million, exchanged $6.1 million of debt for equity, and regained Nasdaq compliance with stockholders' equity requirements following the October 2026 SOD Sciences acquisition. Management expects new clinical initiatives and payer contract renegotiations to contribute to revenue growth beginning Q4 2026.
Prelude Therapeutics reported a Q3 loss of $0.12 per share, beating the consensus estimate of $0.14 loss by 14.29%. Revenue came in at $5.65 million, surpassing estimates by 12.94%, though down from $6.5 million year-over-year. The company has a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. Stock has gained 19% year-to-date versus S&P 500's 10.5% gain.
Journey Medical Corporation reported a Q3 loss of $0.05 per share, missing consensus estimates of $0.03 loss, with revenues of $18.97 million falling 7.66% short of expectations. The company has underperformed the S&P 500 by 53.7% year-to-date and received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions.
ARS Pharmaceuticals reported a Q3 loss of $0.36 per share, missing consensus estimates of $0.34 loss, and posted revenues of $37.71 million, falling 11.66% short of expectations. The stock has declined 73.8% year-to-date and received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.